X-BODY, a biotechnology company, has raised $4.1 million in a venture capital deal, according to a new filing by the company with the Securities and Exchange Commission. The amount was raised from one investor.

X-BODY is a privately held biotechnology company formed in 2008 by industry veterans Richard Wagner, Brant Binder and Gordon Binder. The company's mission is to apply its innovative capabilities to the discovery of human antibodies against high-value therapeutic targets. X-BODY has entered into a number of alliances with other corporations to generate antibody therapeutic candidates. X-BODY's internal efforts are focused on discovering and developing compounds against biologically relevant targets in oncology and ophthalmology.